Kairos Pharma shares fall 3.67% intraday after CEO.CA's Inside the Boardroom update.

martes, 29 de julio de 2025, 10:21 am ET1 min de lectura
KAPA--
Kairos Pharma, Ltd. declined 3.67% in intraday trading. The company was featured in an article on CEO.CA, a leading investor social network in junior resource and venture stocks, which could have influenced the stock's movement. The article, titled "Inside the Boardroom: Kairos Pharma," highlights the company's presence in the biotech landscape, potentially attracting investor attention and causing the stock to fluctuate.

Kairos Pharma shares fall 3.67% intraday after CEO.CA's Inside the Boardroom update.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios